SFPI-FPIM, SRIW, Amerigo Fund, Adjuvant Capital, AdBio Partners, and TheClubDeal led a €44m Series D round in Univercells.

SFPI-FPIM (Société Fédérale de Participation et d'Investissement), SRIW (Regional Investment Company of Wallonia), Amerigo Fund, Adjuvant Capital, AdBio Partners, and TheClubDeal, led a €44m Series D round in Univercells, a life science company, with participation from 3d investors, Global Health Investment Corporation, Biomedical Advanced Research and Development Authority, and In-Q-Tel. “This first Series D closing is another step towards the realization of our mission to make biologics available to all and to successfully address health challenges during and between pandemics. We are committed to continue delivering breakthrough technologies and services that democratize the production of biologics and widen the access to life changing drugs and vaccines. It is a pivotal moment to invest in biomanufacturing capabilities and we are looking forward to enabling our partners, from bio-innovators to governments, for the benefit of all,” Hugues Bultot, Univercells Group co-founder and CEO.